Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo

Digestion

Volumn 57, Issue , 1996, Pages 22-28

  Weckbecker, G ^a   Raulf, F ^a   Tolcsvai, L ^a   Bruns, C ^a  

^a Preclinical Research   (Switzerland)

Author keywords

Anti proliferative; Chemotherapy; Combination therapy; Doxorubicin; Octreotide; SMS 201 995

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; OCTREOTIDE; PACLITAXEL; SOMATOSTATIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; FEMALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTORADIOGRAPHY; CELL DIVISION; DOXORUBICIN; DRUG SYNERGISM; FLUOROURACIL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOMYCIN; NEOPLASM TRANSPLANTATION; OCTREOTIDE; PACLITAXEL; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0029945532     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201388     Document Type: Article

References (27)

1. Mascardo RN, Sherline P: Somatostatin inhibits rapid ccntrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 1982:111:1394-1396.
2. Sctyono-Han B, Hcnkclman MS, Fockens JA, Klijn JGM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987:47:1566-1570.
3. Schally A: Oncological applications of somatostatin analogues. Cancer Res 1988:48:6977- 6985.
4. Evers M, Parekh D, Townsend CM, Thompson JC: Somatostatin and analogues in the treatment of cancer. Ann Surg 1991:213:190-198.
5. Lamberts SWJ, Krenning FP, Reubi J-C: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991:12:450-482.
6. Weckbecker G, Liu R, Tolcsvai L, Bruns C: Antiproliferative effcets of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 1992:52:4973-4978.
7. Weckbeckcr G, Raulf F, Stolz B, Bruns C: Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993:60:245-264.
8. Wcckbecker G, Tolcsvai L, Stolz B, Poliak M. Bruns C: Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7, 12-dimelhylbcnz(a)an-thracenc-induccd rat mammary carcinomas. Cancer Res 1994;54:6334-6337.
9. Reubi JC, Laissue JA: Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 1995;16:110-115.
10. Arnold R, Neuhaus C, Benning R, Schwcrk WB, Trautmann ME, Joseph K. Bruns C: Somatostatin analog Sandostatin and inhibition of tumour growth in patients with metastatic endocrine gastrocnteropancreatic tumors. World J Surg 1993:17:511-519.
11. Hellmann K, Carter SK (eds): Fundamentals of Cancer Chemotherapy. New York, McGraw-Hill. 1987.
12. Wcckbccker G: Biochemical pharmacology and analysis of fluoropvrimidines alone and in combination with modulators. Pharmacol Ther 1991:50:367-424.
13. Vigueric N, Tahiri-Jouti N, Ayral AM, Cambil-lau C, Scemama JL, Bastie MJ, Knuhtscn S, Esteve JP, Pradavrol L, Susini C, Vayssc N: Direct inhibitory effects of a somatostatin analog. SMS 201-995. on AR4-2J cell proliferation via pertussis toxin-sensitive guanosinc triphosphate-binding protein-independent mechanism. Endocrinology 1989:124:1017-1025.
14. Tahiri-Jouti N, Cambillau C, Viguerie N, Vidal C, Buscail L, Saint Laurent N, Vaysse N, Susini C: Characterization of a membrane tyrosine phosphatase in AR42J cells: Regulation by somatostatin. Am J Physiol 1992;262:G1007-G1014.
15. Valeriote F, Lin HS: Synergistic interaction of anticancer agents: A cellular perspective. Cancer Chcmother Rep 1975,59:895-900.
16. Bercnbaum MC: What is synergy? Pharmacol Rev 1989:41:93-141.
17. Bruns C, Dietl MM, Palacios JM. Pless J: Identification and characterization of somatostatin receptors in neonatal rat long bones. Biochem J 1990;265:39-44.
18. Raulf F, Pérez J, Hoyer D, Bruns C: Differential expression of five somatostatin receptor subtypes, sst-1 to 5. in the CNS and peripheral tissue. Digestion 1994:55(suppl 3):46-53.
19. Serri O, Brazeau P, Kachra Z, Posner B: Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysccto-mized rat: Evidence for a direct and indirect mechanism of action. Endocrinology 1992: 130:1816-1821.
20. Lamberts SWJ, von Koetsveld P, Hofland U: The interrelationship between the antimitotic action of the somatostatin analog octreotide and that of cytostatic drugs and suramin. Int J Cancer 1991;48:938-941.
21. Lee JM, Erlich R, Bruckner HW, Roboz J, Beasley J, Ohnuma T: Octreotide acetate (San-dostatin. SMS) increases in vitro accumulation of doxorubicin (DOX). Proc Am Assoc Cancer Res 1993:34:285.
22. Krishan A, Frei E III: Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res 1976:36: 143.
23. Hug V, Johnston D, Finders M, Hortobagyi G: Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res 1986:46:147.
24. Upp JR, Olson D Jr, Poston GJ, Alexander RW, Townsend CM, Thompson JC: Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am Surg 1988; 115:29-35.
25. Bruns C, Weckbeeker G, Raulf F, Liibbert H, Hoyer D: Characterization of somatostatin receptor subtypes. Ciba Found Symp 1995,190: 89-110.
26. Joensuu H, Katka K, Kujari H: Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copcnh) 1992;126:184-185.
27. Cascinu S, Fedeli A, Fedeli SL, Catalano G: Octreotide versus loperamide in the treatment of fluorouracil-induccd diarrhea: A randomized trial. J Clin Oncol 1993; 11:148-151.